{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Blasts+20+Percent+or+More+of+Bone+Marrow+Nucleated+Cells",
    "query": {
      "condition": "Blasts 20 Percent or More of Bone Marrow Nucleated Cells"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 4,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T15:19:55.165Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02257138",
      "title": "Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Blasts More Than 20 Percent of Bone Marrow Nucleated Cells",
        "Blasts More Than 20 Percent of Peripheral Blood White Cells",
        "Myelodysplastic/Myeloproliferative Neoplasm",
        "Recurrent Acute Myeloid Leukemia",
        "Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Ruxolitinib Phosphate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2015-02-12",
      "completion_date": "2021-03-19",
      "has_results": true,
      "last_update_posted_date": "2025-06-08",
      "last_synced_at": "2026-06-10T15:19:55.165Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02257138"
    },
    {
      "nct_id": "NCT03801434",
      "title": "Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "BCR-JAK2 Fusion Protein Expression",
        "Blasts 20 Percent or Less of Peripheral Blood White Cells",
        "Blasts More Than 5 Percent of Bone Marrow Nucleated Cells",
        "Blasts More Than 5 Percent of Peripheral Blood White Cells",
        "Blasts Under 20 Percent of Bone Marrow Nucleated Cells",
        "Chronic Eosinophilic Leukemia, Not Otherwise Specified",
        "Eosinophilia",
        "Hepatomegaly",
        "Hypereosinophilic Syndrome",
        "JAK2 Gene Mutation",
        "Splenomegaly",
        "TEL-JAK2 Fusion Protein Expression"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "William Shomali",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2019-11-15",
      "completion_date": "2028-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-12-23",
      "last_synced_at": "2026-06-10T15:19:55.165Z",
      "location_count": 4,
      "location_summary": "Palo Alto, California • Portland, Oregon • Salt Lake City, Utah + 1 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03801434"
    },
    {
      "nct_id": "NCT03851081",
      "title": "Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Allogeneic Hematopoietic Stem Cell Transplantation Recipient",
        "Blasts 5 Percent or More of Bone Marrow Nucleated Cells",
        "Blasts 5 Percent or More of Peripheral Blood White Cells",
        "CD22 Positive",
        "Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells",
        "Lymphoblasts 20 Percent or More of Peripheral Blood White Cells",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Refractory B Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Inotuzumab Ozogamicin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Vincristine Sulfate Liposome",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-01-21",
      "completion_date": "2024-01-21",
      "has_results": false,
      "last_update_posted_date": "2022-01-28",
      "last_synced_at": "2026-06-10T15:19:55.165Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03851081"
    },
    {
      "nct_id": "NCT04047641",
      "title": "Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Blasts 20 Percent or More of Bone Marrow Nucleated Cells",
        "High Risk Myelodysplastic Syndrome",
        "Recurrent Acute Biphenotypic Leukemia",
        "Recurrent Acute Myeloid Leukemia",
        "Recurrent High Risk Myelodysplastic Syndrome",
        "Refractory Acute Myeloid Leukemia",
        "Refractory High Risk Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Cladribine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Idarubicin",
          "type": "DRUG"
        },
        {
          "name": "Quizartinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2019-10-22",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-17",
      "last_synced_at": "2026-06-10T15:19:55.165Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04047641"
    }
  ]
}